Author:
Kosaka Yoshimasa,Rai Yoshiaki,Masuda Norikazu,Takano Toshimi,Saeki Toshiaki,Nakamura Seigo,Shimazaki Ryutaro,Ito Yoshinori,Tokuda Yutaka,Tamura Kazuo
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Blackwell S, Crawford J (1994) Filgrastim (r-metHuG-CSF) in the chemotherapy setting. In: Morstyn G, Dexter TM (eds) Filgrastim (r-metHuG-CSF) in Clinical Practice. Marcel Dekker, Inc., New York, pp 103–116
2. Bosly A, Bron D, van Hoof A, de Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87:277–283. doi:10.1007/s00277-007-0399-y
3. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI (2004) Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 22:4302–4311. doi:10.1200/JCO.2004.03.213
4. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205. doi:10.1200/JCO.2006.06.4451
5. National Comprehensive Cancer Network (2014) Clinical practice guidelines in oncology: myeloid growth factors, version 1. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf. Accessed 6 June 2014
Cited by
83 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献